Eric Smith, MD, PhD, discusses the use of armored chimeric antigen receptor T cells in multiple myeloma.
Eric Smith, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the use of armored chimeric antigen receptor (CAR) T cells in multiple myeloma.
At Memorial Sloan Kettering, armored CAR T cells are used to encode at least 2 genes, 1 being the CAR itself and the second being a gene that gives T cells an advantage. According to Smith, it could be a proinflammatory cytokine that make T cells better killers. It could also be a ligand that is expressed on the surface and interacts with other cells in the tumor microenvironment.
Age, Disease Burden Are Factors in Early Use of Selinexor in Multiple Myeloma
April 22nd 2024During a Case-Based Roundtable® event, Jonathan L. Kaufman, MD, discussed treatment approaches and the tolerability of a selinexor-containing regimen in a patient with relapsed/refractory multiple myeloma in the first article of a 2-part series.
Read More